Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

654
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

204
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
204

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Gupta et al. Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells. <i>Cancers</i> 2023, <i>15</i>, 2198.

Cancers·2024
Same author

Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells.

Cancers·2023
Same author

A Case of Pituitary Apoplexy and Cavernous Sinus Syndrome during Hemodialysis.

Case reports in endocrinology·2023
Same author

Review of the Metabolic Risk Factors for Increased Severity of Coronavirus Disease-2019.

Cardiology in review·2021
Same author

Hyperglycemia in Medically Critically Ill Patients: Risk Factors and Clinical Outcomes.

The American journal of medicine·2020
Same author

Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management.

Cardiology in review·2019

Related Experiment Video

Updated: Apr 10, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

640

Nilotinib-Associated Destructive Thyroiditis.

Suhalia Bakerywala1, Monica D Schwarcz1, Michael D Goldberg1

  • 1Division of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USA.

Case Reports in Endocrinology
|June 12, 2015
PubMed
Summary
This summary is machine-generated.

Protein tyrosine kinase inhibitors, used for leukemia, can cause destructive thyroiditis leading to thyrotoxicosis. This review examines this unusual side effect, focusing on newer targeted cancer therapies.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.7K

Related Experiment Videos

Last Updated: Apr 10, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

640
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.7K

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Protein tyrosine kinase inhibitors are a key targeted therapy for leukemia, especially chronic myeloid leukemia.
  • Tyrosine kinases regulate cellular growth via signaling pathways.
  • Thyroid dysfunction is an emerging complication of tyrosine kinase inhibitor therapy.

Purpose of the Study:

  • To describe a patient with thyrotoxicosis secondary to destructive thyroiditis from tyrosine kinase inhibitor therapy.
  • To review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction.
  • To discuss the implications for newer second-generation tyrosine kinase inhibitors.

Main Methods:

  • Case report of a patient experiencing thyrotoxicosis.
  • Literature review on tyrosine kinase inhibitors and thyroid dysfunction.
  • Pathophysiological analysis of drug-induced thyroiditis.

Main Results:

  • The patient developed thyrotoxicosis due to destructive thyroiditis.
  • Tyrosine kinase inhibitors can disrupt normal thyroid function.
  • Second-generation inhibitors may also pose a risk for thyroid-related adverse events.

Conclusions:

  • Thyrotoxicosis is an unusual but significant complication of protein tyrosine kinase inhibitor treatment.
  • Understanding the mechanism is crucial for managing patients on these targeted therapies.
  • Clinicians should monitor for thyroid dysfunction in patients receiving tyrosine kinase inhibitors.